Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study

Targeting the epidermal growth factor receptor pathway in pancreatic cancer seems to be an attractive therapeutic approach. This study assessed the efficacy of cetuximab plus the combination of gemcitabine/oxaliplatin in metastatic pancreatic cancer. Eligible subjects had histological or cytological...

Descripción completa

Detalles Bibliográficos
Autores principales: Kullmann, F, Hollerbach, S, Dollinger, M M, Harder, J, Fuchs, M, Messmann, H, Trojan, J, Gäbele, E, Hinke, A, Hollerbach, C, Endlicher, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670003/
https://www.ncbi.nlm.nih.gov/pubmed/19293797
http://dx.doi.org/10.1038/sj.bjc.6604983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670003/
https://www.ncbi.nlm.nih.gov/pubmed/19293797
http://dx.doi.org/10.1038/sj.bjc.6604983

Ejemplares similares